Fluorescence-Based High-Throughput Assay for Identifying SARS-CoV-2 3CLpro Inhibitors
Control the COVID-19 pandemic is the most urgent task for the whole world. The efficacious vaccine and antiviral therapeutics will ultimately be major approaches to control the pandemic. To promote the development of antiviral therapeutics, Creative Biolabs provides global clients with a novel high-throughput assay for identifying SARS-CoV-2 3CLpro Inhibitors.
SARS-CoV-2 generates two proteases that cleave the viral polyprotein, a papain-like protease (PLpro) and a chymotrypsin-like protease (3CLpro). 3CLpro, also known as the main protease or Mpro, is the more conserved viral protease with only 5 amino acid changes between SARS/SARS-like CoVs and SARS-CoV-2, compared to the 102 differences found in PLpro. Humans do not have a homologous 3CLpro, which makes 3CLpro an ideal specific antiviral target. Additionally, 3CLpro has been shown to effectively cleave luciferase-based protease biosensors and fluorescence resonance energy transfer (FRET)-based probes. These findings indicate that 3CLpro could be used as a homologous target for the development of anti-coronavirus drugs that can inhibit the proliferation of various coronaviruses.
Fig.1 Illustration of proteolytic targeting chimeras targeting the degradation of 3CLpro and thereby inhibiting coronavirus assembly and replication. (Liu, 2020)
Given the urgent need for therapeutic agents to treat SARS-CoV-2 infection, a novel high-throughput assay to enable large-scale screening of known drugs. FlipGFP fluoresces only after protease-mediated activation. According to this, a novel method of a fluorescent reporter optimized to detect SARS-CoV-2 3CLpro activity was developed. This assay is performed in human cell culture and does not require biosafety level 3 (BSL3) containment. The inhibition of SARS-CoV-2 3CLpro with a known coronavirus 3CLpro inhibitor, GC376, and the correlation between reporter inhibition and inhibition of SARS-CoV-2 replication has been tested and validated by this fluorescence-based assay.
Fig.2 Diagram of the FlipGFP protease reporter. (Froggatt, 2020)
Control the COVID-19 pandemic is an urgent and important responsibility for the whole world. The advanced fluorescence-based high-throughput assay provides us a new direction. With a comprehensive platform, mature technicians, professional scholars, and years of experience accumulated from antiviral research, Creative Biolabs offers high-quality fluorescence-based high-throughput assay services to global researchers to support the therapeutic development of SARS-CoV-2. If you are interested in the fluorescence-based high-throughput assay, please feel free to contact us for more information.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.